Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05031624 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects
A Phase 1 study, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT05031624 is a Phase 1 study that has completed, run by Celldex Therapeutics. The registered enrollment target is 32 participants.
The verdict
NCT05031624, a Phase 1 study, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a study to determine the safety and pharmacokinetics of CDX-0159 administered subcutaneously in healthy subjects.
Interventions
- DRUG Normal saline
- DRUG CDX-0159
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2022-01-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05031624
The ClinicalTrials.gov registry entry for NCT05031624 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT05031624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05031624 about?
NCT05031624 is a clinical study titled "A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects". This is a study to determine the safety and pharmacokinetics of CDX-0159 administered subcutaneously in healthy subjects.
What is the current status of trial NCT05031624?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2021-08-30. Estimated completion is 2022-01-14.
What interventions are being tested in trial NCT05031624?
The interventions under investigation include: Normal saline (DRUG), CDX-0159 (DRUG).
Who is sponsoring clinical trial NCT05031624?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.